| 產(chǎn)品名稱 |
Vaccinia virus ts mutant |
| 商品貨號(hào) |
B161921 |
| Classification |
Poxviridae, Orthopoxvirus |
| Agent |
Vaccinia virus ts mutant |
| Strain |
IHD-W Dts90 |
| Applications |
The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location A24, the 132 kDa RNA polymerase subunit. Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. It was assigned to Dales EM category O, indicating that it produces immature normal particles and mature particles with aberrant cores. |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
This conditional lethal mutant, originally designated plaque isolate number 9235, was isolated from the IHD-W strain of Vaccinia by S. Dales, selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. It was assigned to Dales EM category O, indicating that it produces immature normal particles and mature particles with aberrant cores. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location A24, the 132 kDa RNA polymerase subunit. The non-permissive incubation temperature is 39.5oC. |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Comments |
This conditional lethal mutant, originally designated plaque isolate number 9235, was isolated from the IHD-W strain of Vaccinia by S. Dales, selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. It was assigned to Dales EM category O, indicating that it produces immature normal particles and mature particles with aberrant cores. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location A24, the 132 kDa RNA polymerase subunit. The non-permissive incubation temperature is 39.5oC. Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Effect on Host |
CPE: enlargement, plaques with rounding and eventual sloughing Cytopathic effects in culture include enlargement and rounding of cells, followed by death and sloughing. |
| Growth Medium |
ATCC® Medium 30-2002: Dulbecco's Modified Eagle's Medium (DMEM)
Fetal Bovine Serum
|
| Recommended Host |
Recommended Host: BSC-40 (ATCC CRL-2761) Production host: BSC-40 (ATCC CRL-2761)
Alternate hosts: MRC-5, BSC-1, HeLa, LLC-MK2 |
| Name of Depositor |
S. Dales, R. Condit |
| References |
Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807
Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746
Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570
Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.
|
